IDH1 MUTATION
Clinical trials for IDH1 MUTATION explained in plain language.
Never miss a new study
Get alerted when new IDH1 MUTATION trials appear
Sign up with your email to follow new studies for IDH1 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for AML patients who fail venetoclax?
Disease control Recruiting nowThis pilot study tests the drug olutasidenib, with or without azacitidine, in 25 adults with a specific type of acute myeloid leukemia (IDH1-mutated) that has returned or not responded after venetoclax treatment. The goal is to see if the cancer can be brought into remission. Par…
Matched conditions: IDH1 MUTATION
Phase: PHASE2 • Sponsor: Timothy Pardee • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill aims to keep AML away after transplant
Disease control Recruiting nowThis phase 2 study tests whether the drug ivosidenib can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 75 adults with a specific IDH1 gene mutation will receive either ivosidenib or a placebo daily. The main goal is to see if the d…
Matched conditions: IDH1 MUTATION
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for young brain cancer patients: targeted drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests whether adding the drug olutasidenib to standard chemotherapy (temozolomide) can help children and young adults with a specific type of brain cancer (IDH1-mutant high-grade glioma) live longer. About 60 participants will receive the combination as maintenance the…
Matched conditions: IDH1 MUTATION
Phase: PHASE2 • Sponsor: Rigel Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Promising Three-Drug cocktail targets tough leukemia mutation
Disease control Recruiting nowThis study tests a combination of three drugs—venetoclax, ivosidenib, and azacitidine—in adults with a specific genetic form of acute myeloid leukemia (IDH1-mutated AML). The goal is to see if this triple therapy can improve remission rates and survival compared to standard treat…
Matched conditions: IDH1 MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New Triple-Drug attack targets tough leukemia
Disease control Recruiting nowThis phase 2 trial is testing a combination of three drugs—olutasidenib, venetoclax, and azacitidine—in adults aged 18-75 with newly diagnosed acute myeloid leukemia that has a specific IDH1 gene mutation. The study aims to see if this combo is safer and works better than standar…
Matched conditions: IDH1 MUTATION
Phase: PHASE2 • Sponsor: Justin Watts, MD • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC